Çocuklarda hematopoetik kök hücrenakli

Kemik iliği nakli günümüzde periferik kan ve göbek kordon kanının da kök hücre kaynağı olarak kullanılabilmesi nedeniyle hematopo- etik kök hücre nakli (HKHN) olarak adlandırılmaktadır. Çocuklarda hematolojik malinitelere ek olarak hemoglobinopatiler, immün ye- tersizlikler, kemik iliği yetersizlikleri ve doğuştan metabolik hastalık- lar gibi birçok hastalıkta kesin tedavi yöntemi olarak kullanılmakta- dır. Altta yatan hastalık dışında nakil sürecinde gelişen enfeksiyonlar ve graft versus host hastalığı prognozu etkileyen en önemli etmen- ler olarak sayılabilir. Bu yazıda kök hücre kaynakları, hazırlama te- davileri, çocuklarda HKHN endikasyonları ve nakil sonrası sorunlar konularında özet bilgiler verilmesi amaçlanmıştır. (Türk Ped Arş 2014; 49: 91-8)

Hematopoetic stem cell transplantation in children

Bone marrow transplantation is called hematopoetic stem cell trans- plantation (HSCT), since peripheral blood and umbilical cord blood can also be used as sources of stem cell currently. In children, bone marrow transplantation is used as a definite treatment method in many diseases including hemoglobinopaties, immune deficiencies, bone marrow failure and congenital metabolic diseases in addition o hematological malignancies. In addition to the underlying dise- ase, the most important factors which have an impact on prognosis nclude infections which develop during the process of transplan- ation and graft-versus-host disease. In this article, it was aimed to give brief information on stem cell sources, preparation therapies, HSCT indications and post-transplantation complications in child- ren. (Türk Ped Arş 2014; 49: 91-8)

PDF

___

Thomas ED, Lochte HL, Lu WC, et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957; 257: 491-6. [CrossRef]
Buckley RH, Lucas ZJ, Hattler BG, et al. Defective cellular immunity associated with chronic mucocutaneous moniliasis and recurrent staphylococcal botryomycosis: immunological reconstitution by allogeneic bone marrow. Clin Exp Immunol 1968; 3: 153-69.
Bach FH, Albertini RJ, Joo P, et al. Bone marrow transplantati- on in a patient with Wiskott-Aldrich syndrome. Lancet 1968; 2: 1364-66. [CrossRef]
Aschan J. Allogeneic haematopoietic stem cell transplantation: current status and future outlook. Br Med Bull 2006; 77-78: 23-36. [CrossRef]
Foeken LM, Green A, Hurley CK, et al. Monitoring the internatio- nal use of unrelated donors for transplantation: the WMDA annu- al reports. Bone Marrow Transplant 2010; 45: 811-8. [CrossRef]
Grupp SA, Frangoul H, Wall D, Pulsipher MA, Levine JE, Schultz KR. Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Childrens Onco- logy Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatr Blood Cancer 2006; 46: 414-21. [CrossRef]
Watanabe T, Takaue Y, Kawano Y, et al. HLA-identical sibling pe- ripheral blood stem cell transplantation in children and adoles- cents. Biol Blood Marrow Transplant 2002; 8: 26-31. [CrossRef]
Benito AI, Gonzalez-Vicent M, Garcia F, et al. Allogeneic pe- ripheral blood stem cell transplantation (PBSCT) from HLA- identical sibling donors in children with hematological disea- ses: a single center pilot study. Bone Marrow Transplant 2001; 28: 537-43. [CrossRef]
Yesilipek MA, Hazar V, Küpesiz A, Kizilörs A, Uguz A, Yegin O. Peripheral blood stem cell transplantation in children with beta-thalassemia. Bone Marrow Transplant 2001; 28: 1037-40. [CrossRef]
Styczynski J, Lapopin M, Elarouci N, et al. Pediatric Sibling Donor Complications of Hematopoetic Stem Cell Collections: EBMT Pediatric Diseases Working Party. Blood 2009: 114; Abs- tract 806.
Pulsipher MA, Levine JE, Hayashi RJ, et al. Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience (PBMTC) 1996-2003. Bone Marrow Transplant 2005; 35: 361-7. [CrossRef]
Pulsipher MA, Nagler A, Iannone R, Nelson RM. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer 2006; 46: 422-33. [CrossRef]
Anderlini P, Rizzo JD, Nugent ML, Schmitz N, Champlin RE, Horowitz MM. Peripheral blood stem cell donation: an analy- sis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant 2001; 27: 689-92. [CrossRef]
Majolino I, Aversa F, Bacigalupo A, Bandini G, Arcese W, Rea- li G. Allogeneic transplants of rhG-CSF-mobilized peripheral blood stem cells (PBSC) from normal donors. GITMO. Gruppo Italiano Trapianto di Midollo Osseo. Haematologica 1995; 80: 40-3.
Schoemans H, Theunissen K, Maertens J, Boogaerts M, Verfa- illie C, Wagner J. Adult umblical cord blood transplantation: a comprehensive review. Bone Marrow Transplant 2006; 38: 83- 93. [CrossRef]
Smith AR, Wagner JE. Alternative haematopoietic stem cell so- urces for transplantation: place of umbilical cord blood. Br J Ha- ematol 2009; 147: 246-61. [CrossRef]
Kelly SS, Sola CBS, de Lima M, Shpall E. Ex vivo expansion of cord blood. Bone Marrow Transplant 2009; 44: 673-81. [CrossRef]
Jaroscak J, Goltry K, Smith A, et al. Augmentation of umbili- cal cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the Aastrom Replicell System. Blood 2003; 101: 5061-7. [CrossRef]
Devine SM, Lazarus HM, Emerson SG. Clinical application of hematopoietic progenitor cell expansion: current status and future prospects. Bone Marrow Transplant 2003; 31: 241-52. [CrossRef]
Magro E, Regidor C, Cabrera R, et al, Early hematopoietic reco- very after single unit UCB transplantation in adults supported by co-infusion of mobilized stem clls from a third party donor. Haematologica 2006; 91: 640-8.
Hamza NS, Fanning L, Tary-Lehmann M, et al. High rate of graft failure after infusion of multiple (3-5) umbilical cord blood (UCB) units in adults with hematologic disorders: role of HLA disparity and UCB graft cell cross immune reactivation (abs- tract). Blood 2003; 98.
Veneris MR, Brunstein C, DFor TE, et al. Risk of relaps (REL) af- ter umbilical cord blood (UCB) transplantation in patients with acute leukemia: marked reduction in recipients of two units. ASH Annual Meeting Abstracts (Abstract 305) 2005; 106: 93a.
Gratwohl A. Principals of conditioning. In: Apperly J, Carreras E, Gluckman E, (eds) . Hematopoetic Stem Cell Transplantation. The EBMT Handbook. European School of Hematology 2008; 128-44.
Ljungman P, Bregni M, Brune M, et al. Allogeneic and autolo- gous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219-34. [CrossRef]
Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19: 2130-8. [CrossRef]
Dini G, Miano M. HSCT for acute myeloid leukemia in child- ren In: Apperly J, Carreras E, Gluckman E Grawthol A, Masszi T, (eds). Hematopoietic stem cell transplantation. 5th editi- on. EBMT Handbook, European School of Hematology 2008: 499-503.
Anak S, Saribeyoglu ET, Bilgen H, et al. Allogeneic versus auto- logous versus peripheral stem cell transplantation in CR1 pe- diatric AML patients: a single center experience. Pediatr Blood Cancer 2005; 44: 654-9. [CrossRef]
Peters C, Schrauder A, Schrappe M, et al. Allogeneic haematopo- ietic stem cell transplantation in children with acute lymphob- lastic leukaemia: the BFM/IBFM/EBMT concepts. Bone Marrow Transplant 2005; 35: 9-11. [CrossRef]
Locatelli F, Zecca M, Messina C, et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in se- cond remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia 2002; 16: 2228-37. [CrossRef]
Borgmann A, von Stackelberg A, Hartmann R, et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood 2003; 101: 3835-9. [CrossRef]
Balduzzi A, Gaipa G, Bonanomi S, et al. Purified autologous grafting in childhood acute lymphoblastic leukemia in second remission: evidence for long-term clinical and molecular re- missions. Leukemia 2001; 15: 50-6. [CrossRef]
Cwynarski K, Roberts IA, Iacobelli S, et al. Stem cell transplanta- tion for chronic myeloid leukemia in children. Blood 2003; 102: 1224-31. [CrossRef]
Claviez A, Canals C, Dierickx D, et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with re- current and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 2060-7. [CrossRef]
Koike K, Matsuda K. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia. Br J Hae- matol 2008; 141: 567-75. [CrossRef]
Yoshimi A, Kojima S, Hirano N. Juvenile myelomonocytic leu- kemia: epidemiology, etiopathogenesis, diagnosis, and manage- ment considerations. Paediatr Drugs 2010; 12: 11-21. [CrossRef]
Caselli D, Aricò M. EBMT paediatric working party. The role of BMT in childhood histiocytoses. Bone Marrow Transplant 2008; 41: S8-13. [CrossRef]
Horne A, Janka G, Maarten Egeler R, et al. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol 2005; 129: 622-30. [CrossRef]
Yoon HS, Im HJ, Moon HN, et al. The outcome of hematopoi- etic stem cell transplantation in Korean children with hemop- hagocytic lymphohistiocytosis. Pediatr Transplant 2010: 14: 735-40. [CrossRef]
Antoine C, Müller S, Cant A, et al. Long-term survival and trans- plantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003; 361: 553-60. [CrossRef]
Marsh JCW, Ball SE, Darbyshire P, et al. Guidelines for the diag- nosis and management of acquired aplastic anemia. Br J Hae- matol 2003; 123: 782-801. [CrossRef]
Chan KW, McDonald L, Lim D, et al. Unrelated cord blood transplantation in children with idiopathic severe aplastic ane- mia. Bone Marrow Transplant 2008; 42: 589-95. [CrossRef]
Gluckman E, Wagner JE. Hematopoetic stem cell transplantati- on in childhood inherited bone marrow failure syndrome. Bone Marrow Transplant 2008; 41: 127-32. [CrossRef]
Dufour C, Svahn J. Fanconi anaemia: new strategies. Bone Mar- row Transplant 2008; 41: 90-5. [CrossRef]
Yesilipek MA, Karasu GT, Kupesiz A, et al. Better posttransplant outcome with fludarabine based conditioning in multitransfu- sed fanconi anemia patients who underwent peripheral blood stem cell transplantation. J Pediatr Hematol Oncol 2009; 31: 512-5. [CrossRef]
Bitan M, Or R, Shapira MY, et al. Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated do- nors. Biol Blood Marrow Transplant 2006; 12: 712-8. [CrossRef]
Rosenberg PS, Alter BP, Ebell W. Cancer risks in Fanconi ane- mia: findings from the German Fanconi Anemia Registry. Hae- matologica 2008; 93: 511-7. [CrossRef]
Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003; 101: 1249-56. [CrossRef]
Roy V, Pérez WS, Eapen M, et al. Bone marrow transplantation for diamond-blackfan anemia. Biol Blood Marrow Transplant 2005; 11: 600-8. [CrossRef]
Yesilipek MA, Hazar V, Kupesiz A, Yegin O. Peripheral stem cell transplantation in a child with amegakaryocytic thrombocyto- penia. Bone Marrow Transplant 2000; 26: 571-2. [CrossRef]
Lackner A, Basu O, Bierings M, et al. Hematopoietic stem cell transplantation for amegakaryocytic thrombocytopenia. Br J Haematol 2000; 109: 773-5. [CrossRef]
Karl Welte, Cornelia Zeidler, Dale DC. Severe congenital neutro- penia. Seminars in Hematology 2006; 43: 189-95. [CrossRef]
Yesilipek MA, Tezcan G, Germeshausen M, et al. Unrelated cord blood transplantation in children with severe congenital neut- ropenia. Pediatr Transplant 2009; 13: 777-81. [CrossRef]
Thomas ED, Buckner CD, Sanders JE, et al. Marrow transplanta- tion for thalassemia. Lancet 1982; 2: 227-8. [CrossRef]
Gaziev D, Lucarelli G. Stem cell transplantation for hemoglobi- nopathies. Curr Opin Pediatr 2003; 15: 24-31. [CrossRef]
Pakakasama S, Hongeng S, Chaisiripoomkere, Chuansumrit A, Sirachainun N, Jootar S. Allogeneic peripheral stem cell trans- plantation in children with homozygous beta-thalassemia and severe beta-thalassemia/Hemoglobin E disease. J Pediatr He- matol Oncol 2004; 26: 248-52. [CrossRef]
Yesilipek MA, Ertem M, Cetin M, et al. HLA-matched family hema- topoetic stem cell transplantation in children with beta thalassemia major: the experience of the Turkish Pediatric Bone Marrow Trans- plantation Group. Pediatr Transplant 2012; 16: 846-51. [CrossRef]
Locatelli F, Rocha V, Reed W, et al. Eurocord Transplant Group. Re- lated umbilical cord blood transplant in patients with thalassemia and sickle cell disease. Blood 2003; 101: 2137-43. [CrossRef]
Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a childrens oncology group study. J Clin Oncol 2009; 27: 1007-3. [CrossRef]
Ladenstein R, Potschger U, Hartman O, et al. 28 years of high- dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant 2008; 41: S118-27. [CrossRef]
Mullinghan CG, Bardy PG. New directionjs in the genomics of allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 127-44. [CrossRef]
Woolfrey AE, Anasetti C, Storer B, et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood 2002; 99: 2002-8. [CrossRef]
Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97: 2962-71. [CrossRef]
Giebel S, Giorgiani G, Martinetti M, et al. Low incidence of severe acute graft-versus-host disease in children given hae- matopoietic stem cell transplantation from unrelated donors prospectively matched for HLA class I and II alleles with high- resolution molecular typing. Bone Marrow Transplant 2003; 31: 987-93. [CrossRef]
Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplanta- tion. Blood 2000; 95: 2754-9.
Goldberg J, Jacobsohn DA, Zahurak ML, Vogelsang GB. Gast- rointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 101-7. [CrossRef]
Sakihama T, Smolyar A, Reinherz EL.Molecular recognition of antigen involves lattice formation between CD4, MHC class II and TCR molecules. Immunol Today 1995; 16: 581-7. [CrossRef]
Via CS, Nguyen P, Shustov A, Drappa J, Elkon KB. A major role for the Fas pathway in acute graft-versus-host disease J Immu- nol 1996; 157: 5387-93.
Sullivan KM, Parkman R. The pathophysiology and treatment of graft-versus-host disease. Clinical Haematology 1983; 12: 775-89. [CrossRef]
Weinberg K, Blazar BR, Wagner JE, et al. Factors affecting thymic function after allogeneic hematopoietic stem cell trans- plantation. Blood 2001; 97: 1458-66. [CrossRef]
Brown JMY. Fungal infections after hematopoietic cell trans- plantation. In: Blume KG, Forman SJ, Appelbaum FR, (eds). Tho- mas hematopoietic cell transplantation. Blackwell Publishing: Malden, 2004.pp.683-700.
Centers for Disease Control and Prevention; Infectious Disea- se Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic in- fections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49: 1-125.
OBrien SN, Blijlevens NM, Mahfouz TH, Anaissie EJ. Infections in patients with hematological cancer: recent developments. Hematology Am Soc Hematol Educ Program 2003; 438-72. [CrossRef]